A Modular Open-label Phase I/II Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of EP0031 in Patients with Advanced RET-altered Malignancies
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Ret Fusion-positive Nsclc, : Ret Mutation-positive Mtc
-
Age: Between 18 Year(s) - 100 Year(s)
-
Gender: Male or Female
-
Other Inclusion Criteria:
- Documented RET-altered malignancy as determined by a DNA- or RNA-based assay of tumour tissue and/or a liquid biopsy
- Tissue or liquid biopsy at screening for retrospective confirmation of RET aberration status, after progression on first-generation SRI
- Ability to swallow and retain oral medication
You may not be eligible for this study if the following are true:
-
- Any other known major driver gene alterations except RET
- Any other invasive malignancy which has been active or treated within the past 3 years
- Spinal cord compression or unstable brain metastases
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.